Immatics (IMTX) Expected to Announce Earnings on Thursday

Immatics (NASDAQ:IMTX) will likely be announcing its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $16.16 million for the quarter.

Immatics Price Performance

IMTX opened at $4.98 on Tuesday. The company has a fifty day moving average price of $5.19 and a 200-day moving average price of $7.84. The firm has a market capitalization of $594.39 million, a P/E ratio of -7.55 and a beta of 0.83. Immatics has a one year low of $4.06 and a one year high of $13.77.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IMTX shares. Bank of America reduced their price target on shares of Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, November 19th. The Goldman Sachs Group upgraded shares of Immatics to a “strong-buy” rating in a research report on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $16.67.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immatics stock. Bank of America Corp DE boosted its holdings in Immatics (NASDAQ:IMTX) by 166.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,575 shares of the company’s stock after purchasing an additional 2,231 shares during the period. Bank of America Corp DE’s holdings in Immatics were worth $25,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.